Educational Intervention
OtherParticipate in educational session with health coach
Other names: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational
NCT Number: NCT04763980
This clinical trial studies barriers to genetic testing in African American men with prostate cancer and whether tailored, culturally relevant genetic testing education provided by a community-based health coach is beneficial in improving knowledge, attitudes, and awareness of genetic testing. Information gained from this study, may help researchers better understand and learn more about how to increase access to germline genetic testing in underrepresented populations.
Interested in participating?
Request Info18 year and older
Male
Interventional
Not applicable
San Francisco Veterans Administration Medical Center, San Francisco, California, United States
PRIMARY OBJECTIVES:
I. To assess uptake of genetic testing using tailored education strategies and culturally relevant cancer resources delivered by a community-based health coach (Initial Pilot Cohorts).
II. To assess barriers to the intervention (Part 1). III. To evaluate consent rate of germline testing among participants receiving the intervention (Part 2).
SECONDARY OBJECTIVES:
I. To assess decisional conflict among African American men receiving tailored education strategies and culturally relevant cancer resources on genetic testing delivered by a community-based health coach (Initial Pilot Cohorts).
II. To assess facilitators to the intervention (Part 1).
III. To assess acceptability of the intervention (Parts 1 and 2).
IV. To characterize patient and health coach use of ProGene (Part 1).
V. To evaluate completion rate of germline testing among participants receiving the intervention (Part 2).
VI. To evaluate change in participant knowledge about germline testing among patient participants (Part 2).
VII. To evaluate change in participant attitudes toward germline testing among patient participants (Part 2).
VIII. To evaluate change in decisional conflict about germline testing among patient participants (Part 2).
IX. To evaluate reach of the intervention (Part 2).
X. To evaluate barriers and facilitators to the intervention (Part 2).
XI. To identify reasons for declining germline testing.
TERTIARY OBJECTIVE:
I. To assess the germline mutation rate among African American men with prostate cancer (Initial Pilot Cohorts)
OUTLINE: The initial pilot phase of the study has concluded. Participants are assigned to Parts 1 or 2 of current study.
CLOSED TO ENROLLMENT: INITIAL PILOT COHORT A:
Participants complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Participants may also undergo genetic testing.
CLOSED TO ENROLLMENT: INITIAL PILOT COHORT B:
Participants engage in an educational session with health coach over 60 minutes. Participants also complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Participants may undergo genetic testing.
PART 1:
Participants engage in an educational session with health coach over 60 minutes. Participants also complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Participants may undergo genetic testing.
PART 2:
Participants in this secondary pilot engage in an educational session with health coach over 60 minutes. Participants also complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Participants may undergo genetic testing.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
CLOSED TO ENROLLMENT: INITIAL PILOT COHORT:
Participants:
ENROLLING: PART 1:
Participants:
Note: Participants may or may not have had germline testing in the past, as a range of experiences is valuable for holistic feedback.
Providers:
ENROLLING: PART 2:
Participants:
Exclusion criteria
CLOSED TO ENROLLMENT: INITIAL PILOT COHORT.
ENROLLING: PART 1:
ENROLLING: PART 2:
Participate in educational session with health coach
Other names: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational
Undergo genetic testing
Other names: Genetic analysis, Genetic Examination, Genetic Test
Complete surveys throughout course of study.
Other names: Questionnaire Administration
AI Platform to be used by health coach during sessions
Other names: ProGene AI Platform, ProGene
Participant and provider interviews will be conducted by study staff.
Other names: Participant interviews
Time frame: At baseline (1 day)
The consent rate for each cohort will be defined as proportion of patients enrolled in the study who agree to undergo germline genetic testing with Color genomics. The point estimate and 90% confidence interval will be provided.
Time frame: Up to 30 days
Participant- and provider-reported barriers to engaging in the intervention for participants to make an informed decision about germline testing will be reported descriptively.
Time frame: Up to 120 days
The decisional conflict scale will be scored using a validated instrument. Scores range from 0 (no decisional conflict) to 100 (extremely high decisional conflict). Summary statistics with median and interquartile range will be obtained.
Time frame: Up to 120 days
Participant- and provider-reported facilitators to engaging in the intervention for participants to make an informed decision about germline testing.
Time frame: Up to 120 days
Participant-reported acceptability of the intervention will be described using the TFA questionnaire. Scores on the TFA items will be averaged across all participants. Items will be scored on a 5-point scale: 1= Completely disagree, 2 = Disagree, 3 = Neither agree nor disagree, 4 = Agree, 5= Completely agree. All negatively worded items will be reverse-scored for a total score of 24-120. Higher scores represent greater acceptability (more positive attitudes). The mean score and standard deviation will be reported.
Time frame: Up to 30 days
The number of recorded data inputs into the ProGene platform will be reported descriptively to characterize patient-participant and health coach use of ProGene.
Time frame: Up to 120 days
The completion rate is defined as the proportion of patient-participants who complete germline testing within 90 days of intervention will be reported.
Time frame: Up to 120 days
Knowledge of tumor genetic testing adapted from a validated survey from Blanchette, et al.+ select questions from a survey from Rogith, et al. will be utilized to measure the level of cancer genomic testing knowledge. "Don't know" will be scored as incorrect. The proportion of correct responses will be calculated to generate a total score between 0-100, with a higher score indicating greater knowledge. No items will be weighted. Since all items are required, we anticipate missing responses will be rare. Any missing data will be managed case-by-case post-hoc.
Time frame: Up to 120 days
Attitude and expectations measure for tumor genetic testing is a 17-item measure adapted from a validated survey from Blanchette, et al. including one open-ended investigator-created item. Items on the attitude scoring scale range from "Yes" = 1 and "No" or "Unsure" = 0
Time frame: Up to 120 days
Proportion of individuals classified as "supporters" of genetic testing
Time frame: Up to 120 days
Proportion of participants who consent to study among those approached as potential participants will be reported
Time frame: Up to 120 days
Participant- and provider-reported barriers to engaging in the intervention for participants to make an informed decision about germline testing will be reported descriptively.
Time frame: Up to 120 days
Patient-participant reported reasons for declining germline testing will be reported descriptively.
Time frame: At baseline and exit/follow-up visit (up to 2 days)
Will be determined by the sum of all alterations detected on Color genomics. Summary statistics will be obtained.
Contact information is provided by the study sponsor or research team.
University of California, San Francisco
Other
Navigate Study: Use of a Community-Based Health Coach to Improve Access to Germline Genetic Testing Among African American Men With Prostate Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07285044
Adenocarcinoma, Adnexal Diseases
Jacksonville, Florida, United States
View Trial DetailsNCT06957691
Adenocarcinoma, Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma
Boston, Massachusetts, United States
View Trial DetailsNCT05438563
Genital Diseases, Genital Diseases, Male
Rochester, Minnesota, United States
View Trial DetailsNCT04857502
Genital Diseases, Genital Diseases, Male
Los Angeles, California, United States
View Trial Details